Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich Sells 1,659 Shares

Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,659 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $10,435.11. Following the transaction, the chief financial officer now directly owns 191,419 shares in the company, valued at approximately $1,204,025.51. This represents a 0.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 10th, Robert Stefanovich sold 1,256 shares of Cryoport stock. The stock was sold at an average price of $4.88, for a total value of $6,129.28.

Cryoport Price Performance

Shares of NASDAQ:CYRX opened at $6.17 on Wednesday. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The company has a market cap of $307.94 million, a P/E ratio of -1.83 and a beta of 1.67. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $20.11. The company has a 50-day moving average price of $6.98 and a 200 day moving average price of $7.43.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the previous year, the business earned ($0.29) EPS. Research analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Cryoport

A number of hedge funds have recently added to or reduced their stakes in CYRX. Point72 Asia Singapore Pte. Ltd. lifted its position in Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Cryoport during the 4th quarter valued at approximately $51,000. Avanza Fonder AB acquired a new stake in shares of Cryoport during the 4th quarter valued at approximately $64,000. Quarry LP acquired a new stake in shares of Cryoport during the 4th quarter valued at approximately $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport during the 3rd quarter valued at approximately $82,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Cryoport in a report on Wednesday, March 5th. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $11.50.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.